Physician profile
Jesse Newman
NPI 1174812655
$3,068.07
in general payments reported to CMS, 2019-2025
22 companies · $66.84 in 2025
The $66.84 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,473 · 2020: $339 · 2022: $52.16 · 2023: $20.87 · 2024: $116 · 2025: $66.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $203.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $449.79 | 2019-2025 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $385.25 | 2019-2024 | Farxiga |
| Pfizer INC. | $298.82 | 2019-2024 | |
| Novo Nordisk INC | $273.02 | 2019-2025 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $228.35 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.59 | 2019-2020 | |
| Lilly USA, LLC | $185.33 | 2019-2022 | |
| Amgen INC. | $156.82 | 2019-2024 | Evenity, Prolia |
| Sanofi-Aventis U.S. LLC | $152.00 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $135.29 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $124.34 | 2019 | |
| Allergan, INC. | $94.05 | 2019-2020 | |
| Amarin Pharma, INC. | $91.98 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $67.98 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $66.44 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $30.34 | 2019 | |
| Novartis Pharmaceuticals Corporation | $28.19 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.98 | 2019 | |
| Inspire Medical Systems, INC. | $19.62 | 2025 | Inspire |
| Mylan Specialty L.P. | $19.54 | 2020 | |
| Abbott Laboratories | $16.73 | 2022 | |
| Aytu Biopharma, INC. | $13.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Newman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.